EEG Biomarkers for OUD: Diagnostic, Prognostic, and Predictive Applications

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Illinois at Chicago
Study ID
NCT07085351
Status
Recruiting
Apply to this trial

Conditions

  • Opiod Use Disorder

Eligibility Criteria

Sex
ALL
Age
22 Years - 85 Years
Healthy Volunteers
Accepted

Study Details

The US is suffering from a national opioid epidemic characterized by significant costs, overdoses, and deaths. Conventional Opioid Use Disorder (OUD) treatments (i.e., pharmacological and psychosocial interventions) are characterized by limited or diminishing efficacy, ceiling effects, and/or serious side effects. The availability of validated OUD biomarkers would be a key step in the development and approval of better treatments. Ultimately, the scarcity of OUD biomarkers represents a significant unmet need in the fight against opioid addiction as recognized by NIDA and the FDA with their support for development of Medical Device Development Tools (MDDT) and biomarker tests for OUD. Advances in neuroimaging techniques, and in particular recent evidence supports electroencephalography (EEG) as a promising candidate to investigate the correlation between addiction and brain state. To address the clear medical and market need for OUD biomarkers, this is a feasibility study to identify and assess potential EEG biomarkers for OUD diagnoses, disease monitoring, and prediction of OUD treatment response.

Key Dates

Start date
Feb 4, 2025
Status verified
Jul 2025
Primary completion
Sep 15, 2025
Completion
Sep 15, 2025

Study Design

Enrollment
70 participants (estimated)

Arms

  • Arm: Opioid Use Disorder
    Diagnosed Opioid Use Disorder subjects will perform 2 EEG sessions done at the initial visit and one week later. EEG recordings will be taken to monitor brain activity
  • Arm: Healthy Control
    Age-matched healthy controls. Subjects will perform 2 EEG sessions done at the initial visit and one week later. EEG recordings will be taken to monitor brain activity

Primary Outcome Measure

Electroencephalogram power in Delta through Gamma bands [ Time Frame: 1 week ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Clinical & Imaging Research Outcomes LabChicagoIllinois60612
Aksarapak Hengyotmark, MD
[email protected]
312-257-4158
Ciro Ramos-Estebanez, MD., Ph.D. (PRINCIPAL_INVESTIGATOR)

Find similar trials in Chicago, IL

By research site
Clinical & Imaging Research Outcomes Lab· Chicago, IL

Related Studies